CRISPR Therapeutics (CRSP) furnishes Q3 2025 results, Exhibit 99.1

CRISPR Therapeutics AG furnished a Form 8‑K announcing its financial results for the quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/10/2025 - 08:10 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

CRISPR Therapeutics AG furnished a Form 8‑K announcing its financial results for the quarter ended September 30, 2025. The company provided the full details in a press release attached as Exhibit 99.1 under Item 2.02.

The materials are furnished, not filed, and therefore are not subject to Section 18 liabilities or incorporated by reference except as specifically stated. The 8‑K was signed by CEO Samarth Kulkarni, Ph.D., on November 10, 2025.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRSP announce in this 8‑K?

CRISPR Therapeutics AG announced financial results for the quarter ended September 30, 2025 under Item 2.02.

How were CRSP’s results provided?

Through a press release furnished as Exhibit 99.1 to the Form 8‑K.

Are the materials considered "filed" under the Exchange Act?

No. They are furnished, not filed, and are not subject to Section 18 liabilities or incorporated by reference unless expressly stated.

When was the announcement made?

November 10, 2025.

Who signed the 8‑K for CRSP?

Samarth Kulkarni, Ph.D., Chief Executive Officer.

What is CRSP’s trading symbol and exchange?

The common shares trade as CRSP on The NASDAQ Global Market.

Which exhibit contains the press release?

Exhibit 99.1 contains the press release; the cover page Inline XBRL is Exhibit 104.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001674416false00-000000000016744162025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

CRISPR THERAPEUTICS AG

(Exact name of registrant as specified in its charter)

Switzerland			001-37923	Not Applicable
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
Baarerstrasse 14
6300 Zug, Switzerland				Not Applicable
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: 41 (0)41 561 32 77

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, nominal value CHF 0.03		CRSP		The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, CRISPR Therapeutics AG announced its financial results for the quarter ended September 30, 2025 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		Press Release by CRISPR Therapeutics AG, dated November 10, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			CRISPR Therapeutics AG
Date:	November 10, 2025	By:	/s/ Samarth Kulkarni
			Samarth Kulkarni, Ph.D. Chief Executive Officer